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Abstract
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available),
plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise
Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time
record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13881/full. Other ion channels are one of the eight major
pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, nuclear hormone receptors, catalytic
receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for
further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16
and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology
(NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
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Aquaporins
Other ion channels → Aquaporins
Overview: Aquaporins and aquaglyceroporins are membrane
channels that allow the permeation of water and certain other
small solutes across the cell membrane. Since the isolation and
cloning of the ﬁrst aquaporin (AQP1) [77], 12 additional members
of the family have been identiﬁed, although little is known about
the functional properties of two of these (AQP11; Q8NBQ7 and
AQP12A; Q8IXF9). The other 11 aquaporins can be divided into
two families (aquaporins and aquaglyceroporins) depending on
whether they are permeable to glycerol [41]. One or more mem-
bers of this family of proteins have been found to be expressed in
almost all tissues of the body. Individual AQP subunits have six
transmembrane domains with an inverted symmetry between the
ﬁrst three and last three domains [15]. Functional AQPs exist as
tetramers but, unusually, each subunit contains a separate pore,
so each channel has four pores.
Nomenclature AQP0 AQP1 AQP2 AQP3 AQP4 AQP5
HGNC, UniProt MIP, P30301 AQP1, P29972 AQP2, P41181 AQP3, Q92482 AQP4, P55087 AQP5, P55064
Permeability water (low) water (high) water (high) water (high), glycerol water (high) water (high)
Endogenous activators – cyclic GMP – – – –
Inhibitors Hg2+ Ag+, Hg2+, tetraethylammonium Hg2+ Hg2+ (also inhibited by
acid pH)
– Hg2+
Comments – – – AQP3 is also inhibited
by acid pH
AQP4 is inhibited
by PKC activation
–
Nomenclature AQP6 AQP7 AQP8 AQP9 AQP10
HGNC, UniProt AQP6, Q13520 AQP7, O14520 AQP8, O94778 AQP9, O43315 AQP10, Q96PS8
Permeability water (low), anions water (high), glycerol water (high) water (low), glycerol water (low), glycerol
Inhibitors Hg2+ Hg2+ Hg2+ Hg2+, phloretin Hg2+
Comments AQP6 is an intracellular channel permeable to anions as
well as water [106]
– – – –
Further reading on Aquaporins
Babey M et al. (2011) Familial forms of diabetes insipidus: clinical and molecular characteristics.
Nat Rev Endocrinol 7: 701-14 [PMID:21727914]
Beitz E et al. (2015) Challenges and achievements in the therapeutic modulation of aquaporin
functionality. Pharmacol Ther 155: 22-35 [PMID:26277280]
Bockenhauer D et al. (2015) Pathophysiology, diagnosis and management of nephrogenic diabetes
insipidus. Nat Rev Nephrol 11: 576-88 [PMID:26077742]
Papadopoulos MC et al. (2013) Aquaporin water channels in the nervous system. Nat Rev Neurosci
14: 265-77 [PMID:23481483]
Verkman AS et al. (2014) Aquaporins: important but elusive drug targets. Nat Rev Drug Discov 13:
259-77 [PMID:24625825]
Searchable database: http://www.guidetopharmacology.org/index.jsp Aquaporins S196
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13881/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Other ion channels. British Journal of Pharmacology (2017) 174, S195–S207
Chloride channels
Other ion channels → Chloride channels
Overview: Chloride channels are a functionally and structurally
diverse group of anion selective channels involved in processes
including the regulation of the excitability of neurones, skeletal,
cardiac and smooth muscle, cell volume regulation, transepithe-
lial salt transport, the acidiﬁcation of internal and extracellular
compartments, the cell cycle and apoptosis (reviewed in [22]).
Excluding the transmittergated GABAA and glycine receptors (see
separate tables), well characterised chloride channels can be clas-
siﬁed as certain members of the voltage-sensitive ClC subfamily,
calcium-activated channels, high (maxi) conductance channels,
the cystic ﬁbrosis transmembrane conductance regulator (CFTR)
and volume regulated channels [101]. No ofﬁcial recommenda-
tion exists regarding the classiﬁcation of chloride channels. Func-
tional chloride channels that have been cloned from, or charac-
terised within, mammalian tissues are listed with the exception
of several classes of intracellular channels (e.g. CLIC) that are re-
viewed by in [26].
ClC family
Other ion channels → Chloride channels → ClC family
Overview: The mammalian ClC family (reviewed in [2, 16, 22,
24, 40]) contains 9 members that fall, on the basis of sequence
homology, into three groups; ClC-1, ClC-2, hClC-Ka (rClC-K1)
and hClC-Kb (rClC-K2); ClC-3 to ClC-5, and ClC-6 and -7. ClC-1
and ClC-2 are plasma membrane chloride channels. ClC-Ka and
ClC-Kb are also plasma membrane channels (largely expressed in
the kidney and inner ear) when associated with barttin (BSND,
Q8WZ55), a 320 amino acid 2TM protein [27]. The localisation
of the remaining members of the ClC family is likely to be pre-
dominantly intracellular in vivo, although they may trafﬁc to the
plasma membrane in overexpression systems. Numerous recent
reports indicate that ClC-4, ClC-5, ClC-6 and ClC-7 (and by in-
ference ClC-3) function as Cl-/H+ antiporters (secondary active
transport), rather than classical Cl- channels [34, 48, 62, 73, 87];
reviewed in [2, 79]). It has recently been reported that the activity
of ClC-5 as a Cl-/H+ exchanger is important for renal endocytosis
[64]. Alternative splicing increases the structural diversity within
the ClC family. The crystal structure of two bacterial ClC proteins
has been described [25] and a eukaryotic ClC transporter (CmCLC)
has recently been described at 3.5 Å resolution [30]. Each ClC sub-
unit, with a complex topology of 18 intramembrane segments,
contributes a single pore to a dimeric ‘double-barrelled’ ClC chan-
nel that contains two independently gated pores, conﬁrming the
predictions of previous functional and structural investigations
(reviewed in [16, 24, 40, 79]). As found for ClC-4, ClC-5, ClC-6
and ClC-7, the prokaryotic ClC homologue (ClC-ec1) and CmCLC
function as H+/Cl antiporters, rather than as ion channels [1, 30].
The generation of monomers from dimeric ClC-ec1 has ﬁrmly es-
tablished that each ClC subunit is a functional unit for transport
and that cross-subunit interaction is not required for Cl-/H+ ex-
change in ClC transporters [81].
Nomenclature ClC-1 ClC-2
HGNC, UniProt CLCN1, P35523 CLCN2, P51788
Endogenous activators – arachidonic acid
Activators – lubiprostone, omeprazole
Channel blockers 9-anthroic acid, S-(-)CPB, S-(-)CPP, Cd2+, Zn2+, fenoﬁbric acid,
niﬂumic acid
GaTx2 (pKd 10.8) [voltage dependent -100mV], Cd
2+, NPPB, Zn2+,
diphenylamine-2-carboxylic acid
Functional Characteristics γ = 1–1.5 pS; voltage-activated (depolarization) (by fast gating of single
protopores and a slower common gate allowing both pores to open
simultaneously); inwardly rectifying; incomplete deactivation upon
repolarization, ATP binding to cytoplasmic cystathionine β-synthetase
related (CBS) domains inhibits ClC-1 (by closure of the common gate),
depending on its redox status
γ = 2–3 pS; voltage-activated by membrane hyperpolarization by fast protopore
and slow cooperative gating; channels only open negative to ECl resulting in
steady-state inward rectiﬁcation; voltage dependence modulated by permeant
anions; activated by cell swelling, PKA, and weak extracellular acidosis;
potentiated by SGK1; inhibited by phosphorylation by p34(cdc2)/cyclin B; cell
surface expression and activity increased by association with Hsp90
Searchable database: http://www.guidetopharmacology.org/index.jsp ClC family S197
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(continued)
Nomenclature ClC-1 ClC-2
Comments CIC-1 is constitutively active CIC-2 is also activated by amidation
Nomenclature ClC-Ka ClC-Kb ClC-3 ClC-4
HGNC, UniProt CLCNKA, P51800 CLCNKB, P51801 CLCN3, P51790 CLCN4, P51793
Activators niﬂumic acid (pEC50 3–5) niﬂumic acid (pEC50 3–5) – –
Channel blockers 3-phenyl-CPP, DIDS,
niﬂumic acid
3-phenyl-CPP, DIDS phloretin (pIC50 4.5) Zn2+ (pIC50 4.3) [68], Cd2+ (pIC50
4.2) [68]
Functional Characteristics γ = 26 pS; linear current-voltage
relationship except at very
negative potentials; no time
dependence; inhibited by
extracellular protons (pK = 7.1);
potentiated by extracellular
Ca2+
Bidirectional rectiﬁcation; no time
dependence; inhibited by
extracellular protons; potentiated
by extracellular Ca2+
Cl-/H+ antiporter [58];
pronounced outward
rectiﬁcation; slow
activation, fast deactivation;
activity enhanced by CaM
kinase II; inhibited by
intracellular Ins(3,4,5,6)P4
and extracellular acidosis
Cl-/H+ antiporter (2Cl-:1H+) [3, 73,
87]; extreme outward rectiﬁcation;
voltage-dependent gating with
midpoint of activation at +73 mV [67];
rapid activation and deactivation;
inhibited by extracellular acidosis;
non-hydrolytic nucleotide binding
required for full activity
Comments CIC-Ka is constitutively active
(when co-expressed with
barttin), and can be blocked by
benzofuran derivatives
CIC-Kb is constitutively active
(when co-expressed with barttin),
and can be blocked by
benzofuran derivatives
insensitive to the channel
blockers DIDS, NPPB and
tamoxifen (10 μM)
–
Nomenclature ClC-5 ClC-6 ClC-7
HGNC, UniProt CLCN5, P51795 CLCN6, P51797 CLCN7, P51798
Channel blockers – DIDS (pIC50 3) DIDS (pIC50 4.4) [90], NS5818 (pIC50
4.3) [90], NPPB (pIC50 3.8) [90]
Functional Characteristics Cl-/H+ antiporter (2Cl-:1H+) [73, 87, 94, 109]; extreme outward
rectiﬁcation; voltage-dependent gating with midpoint of activation
of 116.0 mV; rapid activation and deactivation; potentiated and
inhibited by intracellular and extracellular acidosis, respectively; ATP
binding to cytoplasmic cystathionine β-synthetase related (CBS)
domains activates ClC-5
Cl-/H+ antiporter (2Cl-:1H+) [62];
outward rectiﬁcation, rapid
activation and deactivation
Cl-/H+ antiporter (2Cl-:1H+) [34, 48,
90]; strong outward rectiﬁcation;
voltage-dependent gating with a
threshold more positive than ˜+ 20 mV;
very slow activation and deactivation
Searchable database: http://www.guidetopharmacology.org/index.jsp ClC family S198
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Nomenclature ClC-5 ClC-6 ClC-7
Comments insensitive to the channel blockers DIDS (1 mM),
diphenylamine-2-carboxylic acid (1 mM), 9-anthroic acid (2 mM),
NPPB (0.5 mM) and niﬂumic acid (1 mM)
– active when co-expressed with Ostm1
Comments: ClC channels display the permeability sequence Cl-
> Br- > I- (at physiological pH). ClC-1 has signiﬁcant opening
probability at resting membrane potential, accounting for 75%
of the membrane conductance at rest in skeletal muscle, and is
important for stabilization of the membrane potential. S-(-)CPP,
9-anthroic acid and niﬂumic acid act intracellularly and exhibit a
strongly voltage-dependent block with strong inhibition at nega-
tive voltages and relief of block at depolarized potentials ([49] and
reviewed in [78]). Inhibition of ClC-2 by the peptide GaTx2, from
Leiurus quinquestriatus herbareus venom, is likely to occur through
inhibition of channel gating, rather than direct open channel
blockade [98]. Although ClC-2 can be activated by cell swelling,
it does not correspond to the VRAC channel (see below). Alter-
native potential physiological functions for ClC-2 are reviewed in
[76]. Functional expression of human ClC-Ka and ClC-Kb requires
the presence of barttin [27, 88] reviewed in [29]. The properties of
ClC-Ka/barttin andClC-Kb/barttin tabulated are those observed in
mammalian expression systems: in oocytes the channels display
time- and voltage-dependent gating. The rodent homologue (ClC-
K1) of ClC-Ka demonstrates limited expression as a homomer, but
its function is enhanced by barttin which increases both chan-
nel opening probablility in the physiological range of potentials
[27, 32, 88] reviewed in [29]). ClC-Ka is approximately 5 to 6-fold
more sensitive to block by 3-phenyl-CPP and DIDS than ClC-Kb,
while newly synthesized benzofuran derivatives showed the same
blocking afﬁnity (<10 μM) on both CLC-K isoforms [50]. The
biophysical and pharmacological properties of ClC-3, and the re-
lationship of the protein to the endogenous volume-regulated an-
ion channel(s) VRAC [4, 36] are controversial and further compli-
cated by the possibility that ClC-3 may function as both a Cl-/H+
exchanger and an ion channel [4, 73, 104]. The functional prop-
erties tabulated are those most consistent with the close structural
relationship between ClC-3, ClC-4 and ClC-5. Activation of het-
erologously expressed ClC-3 by cell swelling in response to hypo-
tonic solutions is disputed, as are many other aspects of its regula-
tion. Dependent upon the predominant extracellular anion (e.g.
SCN- versus Cl-), CIC-4 can operate in two transport modes: a slip-
page mode in which behaves as an ion channel and an exchanger
mode in which unitary transport rate is 10-fold lower [3]. Similar
ﬁndings have been made for ClC-5 [108]. ClC-7 associates with a
β subunit, Ostm1, which increases the stability of the former [45]
and is essential for its function [48].
CFTR
Other ion channels → Chloride channels → CFTR
Overview: CFTR, a 12TM, ABC transporter-type protein, is a
cAMP-regulated epithelial cell membrane Cl- channel involved in
normal ﬂuid transport across various epithelia. Of the 1700 muta-
tions identiﬁed in CFTR, the most common is the deletionmutant
F508 (a class 2 mutation) which results in impaired trafﬁcking
of CFTR and reduces its incorporation into the plasma membrane
causing cystic ﬁbrosis (reviewed in [18]). Channels carrying the
F508 mutation that do trafﬁc to the plasma membrane demon-
strate gating defects. Thus, pharmacological restoration of the
function of the F508 mutant would require a compound that
embodies ’corrector’ (i.e. facilitates folding and trafﬁcking to the
cell surface) and ’potentiator’ (i.e. promotes opening of channels
at the cell surface) activities [18]. In addition to acting as an an-
ion channel per se, CFTR may act as a regulator of several other
conductances including inhibition of the epithelial Na channel
(ENaC), calcium activated chloride channels (CaCC) and volume
regulated anion channel (VRAC), activation of the outwardly rec-
tifying chloride channel (ORCC), and enhancement of the sulpho-
nylurea sensitivity of the renal outermedullary potassium channel
(ROMK2), (reviewed in [63]). CFTR also regulates TRPV4, which
provides the Ca2+ signal for regulatory volume decrease in airway
epithelia [6]. The activities of CFTR and the chloride-bicarbonate
exchangers SLC26A3 (DRA) and SLC26A6 (PAT1) are mutually en-
hanced by a physical association between the regulatory (R) do-
main of CFTR and the STAS domain of the SCL26 transporters, an
effect facilitated by PKA-mediated phosphorylation of the R do-
main of CFTR [42].
Searchable database: http://www.guidetopharmacology.org/index.jsp CFTR S199
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Nomenclature CFTR
HGNC, UniProt CFTR, P13569
Activators felodipine (Potentiation) (pKi 8.4) [71], CBIQ (Potentiation), NS004 (Potentiation), UCCF-029 (Potentiation), UCCF-339 (Potentiation), UCCF-853 (Potentiation),
apigenin (Potentiation), capsaicin (Potentiation), genistein (Potentiation), ivacaftor (Potentiation), nimodipine (Potentiation), phenylglycine-01 (Potentiation),
sulfonamide-01 (Potentiation)
Selective inhibitors crofelemer (pIC50 5.2) [99]
Channel blockers glibenclamide (pKi 4.7) [91], intracellular CFTRinh-172 (intracellular application prolongs mean closed time), GaTx1, extracellular GlyH-101
Functional Characteristics γ = 6-10 pS; permeability sequence = Br- ≥ Cl- > I- > F-, (PI/PCl = 0.1–0.85); slight outward rectiﬁcation; phosphorylation necessary for activation by ATP binding at
binding nucleotide binding domains (NBD)1 and 2; positively regulated by PKC and PKGII (tissue speciﬁc); regulated by several interacting proteins including
syntaxin 1A, Munc18 and PDZ domain proteins such as NHERF (EBP50) and CAP70
Comments UCCF-339, UCCF-029, apigenin and genistein are examples of ﬂavones. UCCF-853 and NS004 are examples of benzimidazolones. CBIQ is an example of a
benzoquinoline. felodipine and nimodipine are examples of 1,4-dihydropyridines. phenylglycine-01 is an example of a phenylglycine. sulfonamide-01 is an example
of a sulfonamide. Malonic acid hydrazide conjugates are also CFTR channel blockers (see Verkman and Galietta, 2009 [101])
Comments: In addition to the agents listed in the table, the novel
small molecule, ataluren, induces translational read through of
nonsense mutations in CFTR (reviewed in [93]). Corrector com-
pounds that aid the folding of DF508CFTR to increase the amount
of protein expressed and potentially delivered to the cell surface
include VX-532 (which is also a potentiator), VRT-325, KM11060,
Corr-3a and Corr-4a see [101] for details and structures of Corr-
3a and Corr-4a). Inhibition of CFTR by intracellular applica-
tion of the peptide GaTx1, from Leiurus quinquestriatus herbareus
venom, occurs preferentially for the closed state of the channel
[33]. CFTR contains two cytoplasmic nucleotide binding domains
(NBDs) that bind ATP. A single open-closing cycle is hypothesised
to involve, in sequence: binding of ATP at the N-terminal NBD1,
ATP binding to the C-terminal NBD2 leading to the formation of
an intramolecular NBD1-NBD2 dimer associated with the open
state, and subsequent ATP hydrolysis at NBD2 facilitating disso-
ciation of the dimer and channel closing, and the initiation of a
new gating cycle [5, 59]. Phosphorylation by PKA at sites within
a cytoplasmic regulatory (R) domain facilitates the interaction of
the two NBD domains. PKC (and PKGII within intestinal epithe-
lial cells via guanylinstimulated cyclic GMP formation) positively
regulate CFTR activity.
Calcium activated chloride channel
Other ion channels → Chloride channels → Calcium activated chloride channel
Overview: Chloride channels activated by intracellular calcium
(CaCC) are widely expressed in excitable and non-excitable cells
where they perform diverse functions [37]. The molecular nature
of CaCC has been uncertain with both CLCA, TWEETY andBEST
genes having been considered as likely candidates [22, 38, 51]. It is
now accepted that CLCA expression products are unlikely to form
channels per se and probably function as cell adhesion proteins,
or are secreted [70]. Similarly, TWEETY gene products do not re-
capictulate the properties of endogenous CaCC. The bestrophins
encoded by genes BEST1-4 have a topology more consistent with
ion channels [38] and form chloride channels that are activated by
physiological concentrations of Ca2+, but whether such activation
is direct is not known [38]. However, currents generated by be-
strophin over-expression do not resemble native CaCC currents.
The evidence for and against bestrophin proteins forming CaCC is
critically reviewed by Duran et al. [22]. Recently, a new gene fam-
ily, TMEM16 (anoctamin) consisting of 10 members (TMEM16A-
K; anoctamin 1-10) has been identiﬁed and there is ﬁrm evidence
that some of these members form chloride channels [21, 43].
TMEM16A (anoctamin 1; Ano 1) produces Ca2+-activated Cl- cur-
rents with kinetics similar to native CaCC currents recorded from
different cell types [14, 82, 89, 105]. Knockdown of TMEM16A
greatly reduces currents mediated by calcium-activated chloride
channels in submandibular gland cells [105] and smooth muscle
cells from pulmonary artery [55]. In TMEM16A(-/-) mice secretion
of Ca2+-dependent Cl- secretion by several epithelia is reduced
[69, 82]. Alternative splicing regulates the voltage- and Ca2+- de-
pendence of TMEM16A and such processingmay be tissue-speciﬁc
manner and thus contribute to functional diversity [31]. There
are also reports that TMEM16B (anoctamin 2; Ano 2) supports
CaCC activity (e.g.[74]) and in TMEM16B(-/-) mice Ca-activated
Cl- currents in the main olfactory epithelium (MOE) and in the
vomeronasal organ are virtually absent [11].
Searchable database: http://www.guidetopharmacology.org/index.jsp Calcium activated chloride channel S200
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Nomenclature CaCC
HGNC, UniProt ANO1, Q5XXA6
Endogenous activators intracellular Ca2+
Selective inhibitors crofelemer (pIC50 5.2) [99]
Endogenous channel blockers Ins(3,4,5,6)P4
Channel blockers 9-anthroic acid, DCDPC, DIDS, NPPB, SITS, ﬂufenamic acid, ﬂuoxetine, mibefradil, niﬂumic acid, tannic acid
Functional Characteristics γ = 0.5–5 pS; permeability sequence, SCN- > NO3-> I- > Br- > Cl- > F-; relative permeability of SCN-:Cl- ˜8. I-:Cl- ˜3, aspartate:Cl- ˜0.15, outward rectiﬁcation
(decreased by increasing [Ca2+]i); sensitivity to activation by [Ca2+]i decreased at hyperpolarized potentials; slow activation at positive potentials (accelerated by
increasing [Ca2+]i); rapid deactivation at negative potentials, deactivation kinetics modulated by anions binding to an external site; modulated by redox status
Comments: Blockade of ICl(Ca) by niﬂumic acid, DIDS and
9-anthroic acid is voltage-dependent whereas block by NPPB is
voltage-independent [37]. Extracellular niﬂumic acid; DCDPC
and 9-anthroic acid (but not DIDS) exert a complex effect upon
ICl(Ca) in vascular smooth muscle, enhancing and inhibiting in-
wardly and outwardly directed currents in a manner dependent
upon [Ca2+]i (see [46] for summary). Considerable crossover in
pharmacology with large conductance Ca2+-activated K+ chan-
nels also exists(see [35] for overview). Two novel compounds,
CaCCinh-A01 and CaCCinh-B01 have recently been identiﬁed
as blockers of calcium-activated chloride channels in T84 hu-
man intestinal epithelial cells [19] for structures). Signiﬁcantly,
other novel compounds totally block currents mediated by
TMEM116A, but have only a modest effect upon total current
mediated by CaCC native to T84 cells or human bronchial ep-
ithelial cells, suggesting that TMEM16A is not the predominant
CaCC in such cells [61]. CaMKII modulates CaCC in a tissue
dependent manner (reviewed by [37, 46]). CaMKII inhibitors
block activation of ICl(Ca) in T84 cells but have no effect in parotid
acinar cells. In tracheal and arterial smooth muscle cells, but
not portal vein myocytes, inhibition of CaMKII reduces inacti-
vation of ICl(Ca). Intracellular Ins(3,4,5,6)P4 may act as an en-
dogenous negative regulator of CaCC channels activated by Ca2+,
or CaMKII. Smooth muscle CaCC are also regulated positively by
Ca2+-dependent phosphatase, calcineurin (see [46] for summary).
Maxi chloride channel
Other ion channels → Chloride channels → Maxi chloride channel
Overview: Maxi Cl- channels are high conductance, anion
selective, channels initially characterised in skeletal muscle and
subsequently found in many cell types including neurones, glia,
cardiac muscle, lymphocytes, secreting and absorbing epithelia,
macula densa cells of the kidney and human placenta syncy-
tiotrophoblasts [84]. The physiological signiﬁcance of the maxi
Cl- channel is uncertain, but roles in cell volume regulation and
apoptosis have been claimed. Evidence suggests a role for maxi Cl-
channels as a conductive pathway in the swelling-induced release
of ATP from mouse mammary C127i cells that may be important
for autocrine and paracrine signalling by purines [23, 83]. A sim-
ilar channel mediates ATP release from macula densa cells within
the thick ascending of the loop of Henle in response to changes
in luminal NaCl concentration [9]. A family of human high con-
ductance Cl- channels (TTYH1-3) that resemble Maxi Cl- channels
has been cloned [95], but alternatively, Maxi Cl- channels have
also been suggested to correspond to the voltage-dependent an-
ion channel, VDAC, expressed at the plasma membrane [7, 65].
Searchable database: http://www.guidetopharmacology.org/index.jsp Maxi chloride channel S201
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13881/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: Other ion channels. British Journal of Pharmacology (2017) 174, S195–S207
Nomenclature Maxi Cl-
Activators cytosolic GTPγS, extracellular chlorpromazine, extracellular tamoxifen, extracellular toremifene, extracellular triﬂupromazine
Endogenous channel
blockers
intracellular arachidonic acid
Channel blockers DIDS (pIC50 4.4) [90], extracellular Zn2+ (pIC50 4.3) [68], NPPB (pIC50 3.8) [90], extracellular Gd3+, SITS, diphenylamine-2-carboxylic acid
Functional Characteristics γ = 280-430 pS (main state);
permeability sequence, I > Br > Cl > F > gluconate (PCIPCl = ˜1.5);
ATP is a voltage dependent permeant blocker of single channel activity (PATP/PCl = 0.08–0.1); channel activity increased by patch-excision; channel opening
probability (at steady-state) maximal within approximately ± 20 mV of 0 mV, opening probability decreased at more negative and (commonly) positive potentials
yielding a bell-shaped curve; channel conductance and opening probability regulated by annexin 6
Comments Maxi Cl- is also activated by G protein-coupled receptors and cell swelling. tamoxifen and toremifene are examples of triphenylethylene anti-oestrogens
Comments: Differing ionic conditions may contribute to vari-
able estimates of γ reported in the literature. Inhibition by
arachidonic acid (and cis-unsaturated fatty acids) is voltage-
independent, occurs at an intracellular site, and involves both
channel shut down (Kd = 4–5 μM) and a reduction of γ (Kd
= 13–14 μM). Blockade of channel activity by SITS, DIDS,
Gd3+ and arachidonic acid is paralleled by decreased swelling-
induced release of ATP [23, 83]. Channel activation by anti-
oestrogens in whole cell recordings requires the presence of in-
tracellular nucleotides and is prevented by pre-treatment with
17β-estradiol, bucladesine, or intracellular dialysis with GDPβS
[20]. Activation by tamoxifen is suppressed by low concentra-
tions of okadaic acid, suggesting that a dephosphorylation event
by protein phosphatase PP2A occurs in the activation pathway
[20]. In contrast, 17β-estradiol and tamoxifen appear to directly
inhibit themaxi Cl- channel of human placenta reconstituted into
giant liposomes and recorded in excised patches [80].
Volume regulated chloride channels
Other ion channels → Chloride channels → Volume regulated chloride channels
Overview: Volume activated chloride channels (also termed
VSOAC, volume-sensitive organic osmolyte/anion channel; VRC,
volume regulated channel and VSOR, volume expansion-sensing
outwardly rectifying anion channel) participate in regulatory vol-
ume decrease (RVD) in response to cell swelling. VRAC may also
be important for several other processes including the regulation
of membrane excitability, transcellular Cl- transport, angiogene-
sis, cell proliferation, necrosis, apoptosis, glutamate release from
astrocytes, insulin (INS, P01308) release from pancreatic β cells
and resistance to the anti-cancer drug, cisplatin (reviewed by [10,
60, 63, 66]). VRAC may not be a single entity, but may instead
represent a number of different channels that are expressed to a
variable extent in different tissues and are differentially activated
by cell swelling. In addition to ClC-3 expression products (see
above) several former VRAC candidates including MDR1 (ABCB1
P-glycoprotein), Icln, Band 3 anion exchanger and phospholem-
man are also no longer considered likely to fulﬁl this function (see
reviews [63, 86]).
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Nomenclature VRAC
Activators GTPγS
Endogenous channel blockers intracellular Mg2+, arachidonic acid
Channel blockers 1,9-dideoxyforskolin, 9-anthroic acid, DCPIB, DIDS, IAA-94, NPPB, NS3728, carbenoxolone, clomiphene, diBA-(5)-C4, gossypol, meﬂoquine, mibefradil,
nafoxidine, nordihydroguiaretic acid, quinidine, quinine, tamoxifen
Functional Characteristics γ = 10–20 pS (negative potentials), 50–90 pS (positive potentials); permeability sequence SCN > I > NO-3 >Br
- > Cl- > F- > gluconate; outward rectiﬁcation
due to voltage dependence of γ; inactivates at positive potentials in many, but not all, cell types; time dependent inactivation at positive potentials; intracellular
ionic strength modulates sensitivity to cell swelling and rate of channel activation; rate of swelling-induced activation is modulated by intracellular ATP
concentration; ATP dependence is independent of hydrolysis and modulated by rate of cell swelling; inhibited by increased intracellular free Mg2+ concentration;
swelling induced activation of several intracellular signalling cascades may be permissive of, but not essential to, the activation of VRAC including: the Rho-Rho
kinase-MLCK; Ras-Raf-MEK-ERK; PIK3-NOX-H2O2 and Src-PLCγ-Ca2+ pathways; regulation by PKCα required for optimal activity; cholesterol depletion enhances
activity; activated by direct stretch of β1-integrin
Comments VRAC is also activated by cell swelling and low intracellular ionic strength. VRAC is also blocked by chromones, extracellular nucleotides and nucleoside analogues
Comments: In addition to conducting monovalent anions, in many cell types the activation of VRAC by a hypotonic stimulus can allow the efﬂux of organic osmolytes such as amino acids and polyols
that may contribute to RVD.
Comments on Chloride channels: Other chloride chan-
nels
In addition to some intracellular chloride channels that are not
considered here, plasma membrane channels other than those
listed have been functionally described. Many cells and tis-
sues contain outwardly rectifying chloride channels (ORCC) that
may correspond to VRAC active under isotonic conditions. A
cyclic AMP-activated Cl- channel that does not correspond to
CFTR has been described in intestinal Paneth cells [100]. A Cl
channel activated by cyclic GMP with a dependence on raised
intracellular Ca2+ has been recorded in various vascular smooth
muscle cells types, which has a pharmacology and biophysical
characteristics very different from the ‘conventional’ CaCC [56,
75]. It has been proposed that bestrophin-3 (BEST3, Q8N1M1) is
an essential component of the cyclic GMP-activated channel [57].
A proton-activated, outwardly rectifying anion channel has also
been described [44].
Further reading on Chloride channels
Adkins GB et al. (2015) Potential role of cardiac chloride channels and transporters as novel thera-
peutic targets. Pharmacol Ther 145: 67-75 [PMID:25160469]
Huang F et al. (2012) International Union of Basic and Clinical Pharmacology. LXXXV: calcium-
activated chloride channels. Pharmacol Rev 64: 1-15 [PMID:22090471]
Kamaleddin MA. (2017) Molecular, biophysical, and pharmacological properties of calcium-
activated chloride channels. J Cell Physiol [PMID:28121009]
Kunzelmann K. (2015) TMEM16, LRRC8A, bestrophin: chloride channels controlled by Ca(2+) and
cell volume. Trends Biochem Sci 40: 535-43 [PMID:26254230]
Pedersen SF et al. (2016) Biophysics and Physiology of the Volume-Regulated Anion Channel
(VRAC)/Volume-Sensitive Outwardly Rectifying Anion Channel (VSOR). Pﬂugers Arch 468:
371-83 [PMID:26739710]
Peretti M et al. (2015) Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4
(CLIC1 AND CLIC4) proteins in tumor development and as novel therapeutic targets. Biochim
Biophys Acta 1848: 2523-31 [PMID:25546839]
Poroca DR et al. (2017) ClC Channels and Transporters: Structure, Physiological Functions, and
Implications in Human Chloride Channelopathies. Front Pharmacol 8: 151 [PMID:28386229]
Sabirov RZ et al. (2016) The properties, functions, and pathophysiology of maxi-anion channels.
Pﬂugers Arch 468: 405-20 [PMID:26733413]
Zegarra-Moran O et al. (2017) CFTR pharmacology. Cell Mol Life Sci 74: 117-128 [PMID:27704174]
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Connexins and Pannexins
Other ion channels → Connexins and Pannexins
Overview: Gap junctions are essential for many physiological
processes including cardiac and smooth muscle contraction, regu-
lation of neuronal excitability and epithelial electrolyte transport
[13, 17, 28]. Gap junction channels allow the passive diffusion
of molecules of up to 1,000 Daltons which can include nutrients,
metabolites and second messengers (such as IP3) as well as cations
and anions. 21 connexin genes and 3 pannexin genes which
are structurally related to the invertebrate innexin genes) code
for gap junction proteins in humans. Each connexin gap junc-
tion comprises 2 hemichannels or ’connexons’ which are them-
selves formed from 6 connexin molecules. The various connexins
have been observed to combine into both homomeric and het-
eromeric combinations, each of whichmay exhibit different func-
tional properties. It is also suggested that individual hemichannels
formed by a number of different connexins might be functional in
at least some cells [39]. Connexins have a common topology, with
four α-helical transmembrane domains, two extracellular loops, a
cytoplasmic loop, and N- and C-termini located on the cytoplas-
mic membrane face. In mice, the most abundant connexins in
electrical synapses in the brain seem to be Cx36, Cx45 and Cx57
[97]. Mutations in connexin genes are associated with the occur-
rence of a number of pathologies, such as peripheral neuropathies,
cardiovascular diseases and hereditary deafness. The pannexin
genes Px1 and Px2 are widely expressed in the mammalian brain
[102]. Like the connexins, at least some of the pannexins can form
hemichannels [13, 72].
Nomenclature Cx23 Cx25 Cx26 Cx30 Cx30.2 Cx30.3 Cx31
HGNC, UniProt GJE1, A6NN92 GJB7, Q6PEY0 GJB2, P29033 GJB6, O95452 GJC3, Q8NFK1 GJB4, Q9NTQ9 GJB3, O75712
Endogenous
inhibitors
extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, ﬂufenamic acid, octanol
Nomenclature Cx31.1 Cx31.9 Cx32 Cx36 Cx37 Cx40 Cx40.1
HGNC, UniProt GJB5, O95377 GJD3, Q8N144 GJB1, P08034 GJD2, Q9UKL4 GJA4, P35212 GJA5, P36382 GJD4, Q96KN9
Endogenous
inhibitors
extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, ﬂufenamic acid, octanol
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Nomenclature Cx43 Cx45 Cx46 Cx47 Cx50 Cx59 Cx62
HGNC, UniProt GJA1, P17302 GJC1, P36383 GJA3, Q9Y6H8 GJC2, Q5T442 GJA8, P48165 GJA9, P57773 GJA10,
Q969M2
Endogenous
inhibitors
extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, ﬂufenamic acid, octanol
Nomenclature Px1 Px2 Px3
HGNC, UniProt PANX1, Q96RD7 PANX2, Q96RD6 PANX3, Q96QZ0
Inhibitors carbenoxolone, ﬂufenamic acid (little block by ﬂufenamic acid)
Comments Unaffected by raising external Ca2+
Comments: Connexins are most commonly named according
to their molecular weights, so, for example, Cx23 is the connexin
protein of 23 kDa. This can cause confusion when comparing be-
tween species – for example, the mouse connexin Cx57 is orthol-
ogous to the human connexin Cx62. No natural toxin or speciﬁc
inhibitor of junctional channels has been identiﬁed yet however
two compounds often used experimentally to block connexins are
carbenoxolone and ﬂufenamic acid [85]. At least some pannexin
hemichannels are more sensitive to carbenoxolone than connex-
ins but much less sensitive to ﬂufenamic acid [12]. It has been
suggested that 2-aminoethoxydiphenyl borate (2-APB) may be a
more effective blocker of some connexin channel subtypes (Cx26,
Cx30, Cx36, Cx40, Cx45, Cx50) compared to others (Cx32, Cx43,
Cx46, [8]).
Further reading on Connexins and Pannexins
Decrock E et al. (2015) Connexin and pannexin signaling pathways, an architectural blueprint for
CNS physiology and pathology? Cell Mol Life Sci 72: 2823-51 [PMID:26118660]
Esseltine JL et al. (2016) Next-Generation Connexin and Pannexin Cell Biology. Trends Cell Biol 26:
944-955 [PMID:27339936]
Freund-Michel V et al. (2016) Expression and role of connexin-based gap junctions in pulmonary
inﬂammatory diseases. Pharmacol Ther 164: 105-19 [PMID:27126473]
Saez JC et al. (2015) Regulation of pannexin and connexin channels and their functional role in
skeletal muscles. Cell Mol Life Sci 72: 2929-35 [PMID:26084874]
Thompson RJ (2015) Pannexin channels and ischaemia. J Physiol 593: 3463-70 [PMID:25384783]
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Sodium leak channel, non-selective
Other ion channels → Sodium leak channel, non-selective
Overview: The sodium leak channel, non selective
(NC-IUPHAR tentatively recommends the nomencla-
ture NaVi2.1, W.A. Catterall, personal communication)
is structurally a member of the family of voltage-gated sodium
channel family (Nav1.1 – Nav1.9) [47, 107]. In contrast to the
latter, NaVi2.1, is voltage-insensitive (denoted in the subscript
‘vi’ in the tentative nomenclature) and possesses distinctive ion
selectivity and pharmacological properties. NaVi2.1, which is
insensitive to tetrodotoxin (10 μM), has been proposed to me-
diate the tetrodotoxin-resistant and voltage-insensitive Na+ leak
current (IL-Na) observed in many types of neurone [52]. However,
whether NaVi2.1 is constitutively active has been challenged [96].
NaVi2.1 is widely distributed within the central nervous system
and is also expressed in the heart and pancreas speciﬁcally, in
rodents, within the islets of Langerhans [47, 52].
Nomenclature Navi2.1
HGNC, UniProt NALCN, Q8IZF0
Activators Constitutively active [52], or activated downstream of Src family tyrosine kinases (SFKs) [53, 96]; positively modulated by decreased extracellular Ca2+ concentration
[54]
Channel blockers Gd3+ (pIC50 5.6), Cd2+ (pIC50 3.8), Co2+ (pIC50 3.6), verapamil (pIC50 3.4)
Functional Characteristics γ = 27 pS (by ﬂuctuation analysis), PNa/PCs = 1.3, PK/PCs = 1.2, PCa/PCs = 0.5, linear current voltage-relationship, voltage-independent and non-inactivating
Comments: In native and recombinant expression systems
NaVi2.1 can be activated by stimulation of NK1 (in hippocam-
pal neurones), neurotensin (in ventral tegmental area neurones)
andM3muscarinic acetylcholine receptors (in MIN6 pancreatic β-
cells) and in amanner that is independent of signalling through G
proteins [53, 96]. Pharmacological and molecular biological evi-
dence indicates such modulation to occur though a pathway that
involves the activation of Src family tyrosine kinases. It is sug-
gested that NaVi2.1 exists as a macromolecular complex with M3
receptors [96] and peptide receptors [53], in the latter instance in
association with the protein UNC-80, which recruits Src to the
channel complex [53, 103]. By contrast, stimulation of Navi2.1
by decreased extracellular Ca2+ concentration is G-protein de-
pendent and involves a Ca2+-sensing G protein-coupled recep-
tor and UNC80 which links Navi2.1 to the protein UNC79 in
the same complex [54]. NaVi2.1 null mutant mice have severe
disturbances in respiratory rhythm and die within 24 hours of
birth [52]. Navi2.1 heterozygous knockout mice display increased
serum sodium concentrations in comparison to wildtype litter-
mates and a role for the channel in osmoregulation has been pos-
tulated [92].
Further reading on Sodium leak channel
Cochet-Bissuel M et al. (2014) The sodium leak channel, NALCN, in health and disease. Front Cell
Neurosci 8: 132 [PMID:24904279]
Lu TZ et al. (2012) NALCN: a regulator of pacemaker activity. Mol Neurobiol 45: 415-23
[PMID:22476981]
Waxman SG et al. (2014) Regulating excitability of peripheral afferents: emerging ion channel tar-
gets. Nat Neurosci 17: 153-63 [PMID:24473263]
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